Literature DB >> 8215287

Inhibition of Toxoplasma gondii protein synthesis by azithromycin.

J Blais1, V Garneau, S Chamberland.   

Abstract

Azithromycin was shown to specifically inhibit the protein synthesis of Toxoplasma gondii in experimental systems by using free tachyzoites and T. gondii-infected mouse macrophages. RNA synthesis of the parasite was not affected by azithromycin. Inhibition of protein synthesis was also proportional to the relative anti-Toxoplasma activity of three macrolides.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8215287      PMCID： PMC188046          DOI： 10.1128/AAC.37.8.1701

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

Review 1.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Use of mouse macrophage cell lines for in vitro propagation of Toxoplasma gondii RH tachyzoites.

Authors:  S Chamberland; W L Current
Journal:  Proc Soc Exp Biol Med       Date:  1991-06

3.  Specific labeling of intracellular Toxoplasma gondii with uracil.

Authors:  E R Pfefferkorn; L C Pfefferkorn
Journal:  J Protozool       Date:  1977-08

4.  Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors:  J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

5.  Intracellular accumulation of azithromycin by cultured human fibroblasts.

Authors:  R P Gladue; M E Snider
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection.

Authors:  R P Gladue; G M Bright; R E Isaacson; M F Newborg
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

7.  Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides.

Authors:  G M Bright; A A Nagel; J Bordner; K A Desai; J N Dibrino; J Nowakowska; L Vincent; R M Watrous; F C Sciavolino; A R English
Journal:  J Antibiot (Tokyo)       Date:  1988-08       Impact factor: 2.649

8.  Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay.

Authors:  S Chamberland; H A Kirst; W L Current
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

9.  In vivo and in vitro activity of roxithromycin against Toxoplasma gondii in mice.

Authors:  B J Luft
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

10.  Recognition of Toxoplasma gondii excreted and secreted antigens by human sera from acquired and congenital toxoplasmosis: identification of markers of acute and chronic infection.

Authors:  A Decoster; F Darcy; A Capron
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330
View more
  9 in total

1.  Effect of clindamycin on intracellular replication, protein synthesis, and infectivity of Toxoplasma gondii.

Authors:  J Blais; C Tardif; S Chamberland
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

2.  Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis.

Authors:  Eglal I Amer; Maha M Eissa; Shereen F Mossallam
Journal:  J Parasit Dis       Date:  2014-08-31

3.  Effects of 2',3'-dideoxyinosine on Toxoplasma gondii cysts in mice.

Authors:  M E Sarciron; P Lawton; C Saccharin; A F Petavy; F Peyron
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

4.  Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics.

Authors:  C J Beckers; D S Roos; R G Donald; B J Luft; J C Schwab; Y Cao; K A Joiner
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

5.  In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii.

Authors:  L Cantin; S Chamberland
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

6.  Evaluation of drug effects on Toxoplasma gondii nuclear and plastid DNA replication using real-time PCR.

Authors:  Qing Zhao; Ming Zhang; Lingxian Hong; Kefu Zhou; Yuguang Lin
Journal:  Parasitol Res       Date:  2010-02-26       Impact factor: 2.289

7.  Localization of azithromycin in Toxoplasma gondii-infected cells.

Authors:  J C Schwab; Y Cao; M R Slowik; K A Joiner
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

8.  Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin.

Authors:  E R Pfefferkorn; S E Borotz
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

9.  Oral administration of azithromycin ameliorates trypanosomosis in Trypanosoma congolense-infected mice.

Authors:  Nthatisi Innocentia Molefe; Shino Yamasaki; Adrian Miki C Macalanda; Keisuke Suganuma; Kenichi Watanabe; Xuenan Xuan; Noboru Inoue
Journal:  Parasitol Res       Date:  2017-07-04       Impact factor: 2.289
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.